Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population

Authors: Yu-Mei Wang, Zhe-Xuan Li, Fu-Bing Tang, Yang Zhang, Tong Zhou, Lian Zhang, Jun-Ling Ma, Wei-Cheng You, Kai-Feng Pan

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Helicobacter pylori (H. pylori) infection and cytokine-mediated inflammatory responses play important roles in gastric cancer (GC) pathogenesis. To investigate an association between genetic polymorphisms in interleukin (IL)-1β, IL-4R, IL-8, IL-10, IL-16, IL-18RAP, IL-22, and IL-32 and risks of GC and its precursors, a population-based study was conducted in Linqu County. Genotypes were determined by Sequenom MassARRAY platform in 132 GC cases and 1198 subjects with gastric lesions. The H. pylori status was determined by 13C-urea breath test (13C-UBT) or enzyme-linked immunosorbent assay (ELISA). Among 11 candidate single nucleotide polymorphisms (SNPs), subjects carrying IL-18RAP rs917997 AA genotype were associated with risk of GC [adjusted odds ratio (OR) = 1.83, 95 % confidence interval (CI) 1.14–2.92] or chronic atrophic gastritis (CAG; OR = 1.55, 95 % CI 1.07–2.24). The risk of GC was also increased in subjects carrying IL-32 rs2015620 A allele (AA + AT; OR = 1.92, 95 % CI 1.09–3.39). Moreover, elevated risks of CAG (OR = 2.64, 95 % CI 1.89–3.69), intestinal metaplasia (IM; OR = 5.58, 95 % CI 3.86–8.05), and dysplasia (DYS; OR = 1.64, 95 % CI 1.18–2.26) were observed in subjects with IL-22 rs1179251 CC genotype. Stratified analysis indicated that risks of GC and its precursors were elevated in subjects with IL-32 rs2015620 A allele (AA + AT) or IL-22 rs1179251 CC genotype and H. pylori infection, and significant interactions between these two SNPs and H. pylori infection were found. These findings suggested that IL-18RAP rs917997, IL-32 rs2015620, IL-22 rs1179251, and interactions between these polymorphisms and H. pylori infection were associated with risks of gastric lesions. Genetic polymorphisms of interleukins may play crucial roles in H. pylori-induced gastric carcinogenesis.
Appendix
Available only for authorised users
Literature
1.
IARC: Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013.
2.
Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–60.PubMed
3.
Peek Jr RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.CrossRefPubMed
4.
5.
You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–83.CrossRefPubMed
6.
Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–92.CrossRefPubMedPubMedCentral
7.
Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–99.CrossRefPubMed
8.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed
9.
10.
Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer. 2002;100:249–60.CrossRefPubMed
11.
12.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004;202:275–93.CrossRefPubMed
13.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.CrossRefPubMed
14.
Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-1b, IL-1rn, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. Carcinogenesis. 2005;26:631–6.CrossRefPubMed
15.
Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S. IL-2-330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (gep-nets). J Mol Med (Berl). 2010;88:423–9.CrossRef
16.
Burada F, Angelescu C, Mitrut P, Ciurea T, Cruce M, Saftoiu A, et al. Interleukin-4 receptor -3223t→c polymorphism is associated with increased gastric adenocarcinoma risk. Can J Gastroenterol. 2012;26:532–6.CrossRefPubMedPubMedCentral
17.
Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S. Il-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETS). Exp Mol Pathol. 2007;83:474–9.CrossRefPubMed
18.
Walczak A, Przybylowska K, Trzcinski R, Sygut A, Dziki L, Dziki A, et al. Association of −1112 c/t promoter region polymorphism of the interleukin 13 gene with occurrence of colorectal cancer. Pol Przegl Chir. 2011;83:27–31.PubMed
19.
Zhang T, Wang H. Variants of interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev. 2013;14:5269–73.CrossRefPubMed
20.
Zhernakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monsuur AJ, et al. Genetic analysis of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008;82:1202–10.CrossRefPubMedPubMedCentral
21.
Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control. 2010;21:1165–70.CrossRefPubMed
22.
Li M, Edamatsu H, Kitazawa R, Kitazawa S, Kataoka T. Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis. Carcinogenesis. 2009;30:1424–32.CrossRefPubMed
23.
Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278:35458–64.CrossRefPubMed
24.
Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J, et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet. 2011;43:1215–8.CrossRefPubMed
25.
You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst. 2000;92:1607–12.CrossRefPubMed
26.
Pan KF, Formichella L, Zhang L, Zhang Y, Ma JL, Li ZX, et al. Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population. Int J Cancer. 2014;134:2118–25.CrossRefPubMed
27.
Zhang L, Blot WJ, You WC, Chang YS, Kneller RW, Jin ML, et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev. 1996;5:627–30.PubMed
28.
Klein PD, Malaty HM, Martin RF, Graham KS, Genta RM, Graham DY. Noninvasive detection of helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol. 1996;91:690–4.PubMed
29.
You WC, Zhang L, Gail MH, Ma JL, Chang YS, Blot WJ, et al. Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. Int J Epidemiol. 1998;27:941–4.CrossRefPubMed
30.
Pages F, Berger A, Lebel-Binay S, Zinzindohoue F, Danel C, Piqueras B, et al. Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett. 2000;75:9–14.CrossRefPubMed
31.
Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem. 1998;273:29445–50.CrossRefPubMed
32.
Cheung H, Chen NJ, Cao Z, Ono N, Ohashi PS, Yeh WC. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol. 2005;174:5351–7.CrossRefPubMed
33.
Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2012;107:1331–41.CrossRefPubMed
34.
Hedl M, Zheng S, Abraham C. The IL18rap region disease polymorphism decreases IL-18rap/IL-18r1/IL-1r1 expression and signaling through innate receptor-initiated pathways. J Immunol. 2014;192:5924–32.CrossRefPubMedPubMedCentral
35.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22:131–42.PubMed
36.
Ishigami S, Arigami T, Uchikado Y, Setoyama T, Kita Y, Sasaki K, et al. IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol. 2013;30:472.CrossRefPubMed
37.
Joosten LA, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Cell Mol Life Sci. 2013;70:3883–92.CrossRefPubMed
38.
Vivier E, Spits H, Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol. 2009;9:229–34.CrossRefPubMed
39.
Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem. 2011;353:41–6.CrossRefPubMed
40.
Qin SY, Yang XW, Luo W, Chen M, Liu ZL, Su SB, Jiang HX: Association of interleukin 22 polymorphisms with gastric cancer risk. Tumour Biol 2014.
41.
Chen JP, Wu MS, Kuo SH, Liao F. IL-22 negatively regulates helicobacter pylori-induced CCL20 expression in gastric epithelial cells. PLoS One. 2014;9, e97350.CrossRefPubMedPubMedCentral
42.
Lim C, Savan R. The role of the IL-22/IL-22r1 axis in cancer. Cytokine Growth Factor Rev. 2014;25:257–71.CrossRefPubMed
43.
Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol Today. 1996;17:476–81.CrossRefPubMed
44.
Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000;100:63–9.CrossRefPubMedPubMedCentral
45.
Burkart KM, Barton SJ, Holloway JW, Yang IA, Cakebread JA, Cruikshank W, et al. Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol. 2006;117:86–91.CrossRefPubMed
46.
Xu LL, Song ZC, Shang K, Zhao LQ, Zhu ZS. Non-association of IL-16 rs4778889 T/C polymorphism with cancer risk in Asians: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:803–5.CrossRefPubMed
47.
48.
Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1b and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol. 2010;25:1604–17.CrossRefPubMed
49.
Hackstein H, Hecker M, Kruse S, Bohnert A, Ober C, Deichmann KA, et al. A novel polymorphism in the 5′ promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics. 2001;53:264–9.CrossRefPubMed
50.
Kato I, Canzian F, Franceschi S, Plummer M, van Doorn LJ, Lu Y, et al. Genetic polymorphisms in anti-inflammatory cytokine signaling and the prevalence of gastric precancerous lesions in Venezuela. Cancer Causes Control. 2006;17:1183–91.CrossRefPubMed
51.
Zeng HM, Pan KF, Zhang Y, Zhang L, Ma JL, Zhou T, et al. Genetic variants of toll-like receptor 2 and 5, Helicobacter pylori infection, and risk of gastric cancer and its precursors in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2011;20:2594–602.CrossRefPubMed
Metadata
Title
Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population
Authors
Yu-Mei Wang
Zhe-Xuan Li
Fu-Bing Tang
Yang Zhang
Tong Zhou
Lian Zhang
Jun-Ling Ma
Wei-Cheng You
Kai-Feng Pan
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4022-x

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

The role of Kaposi’s sarcoma-associated herpesvirus infection in the proliferation of human bladder cancer cells

Original Article

Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21

Original Article

CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation pattern in sporadic colorectal cancer

Original Article

Evaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese population

Original Article

A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma

Original Article

Upregulated expression of long non-coding RNA LINC00982 regulates cell proliferation and its clinical relevance in patients with gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits